A new study from the lab of Markey Cancer Director Mark Evers, M.D., demonstrates the critical role of the hormone neurotensin in cell proliferation and stem cell function in the small intestine.
A recent study demonstrates that a combination of two drugs used together provides better than expected results, providing a promising treatment strategy for patients with recurrent ovarian cancer.
Lt. Gov. Coleman and several of Kentucky’s female legislators joined UK HealthCare to highlight the work of the Markey Cancer Center's Ovarian Cancer Screening Program.
The initiative aims to create a connected, integrated statewide cancer provider network. 40% of all new cancer cases in Kentucky are directly or indirectly cared for by Markey.
Additionally, UK HealthCare was ranked as high-performing in four U.S. News adult specialties: Gastroenterology & GI Surgery, Geriatrics, Orthopedics and Urology.
The consortium is expected to generate infrastructure and strengthen global cancer research leadership and mentorship at the participating institutions.
The new complex — with an estimated 320,000 square feet for cancer services — may include multiple buildings but will primarily allow for the needed expansion of patient care services and increased ease of access for the UK Markey Cancer Center.
Recently published in Supportive Care in Cancer, a team from Markey Cancer Center utilized Kentucky Cancer Registry data to identify if there was a correlation between individuals suffering from financial toxicity and comprehension of health insurance.
The UK Markey Cancer Center has officially launched a unique new clinical trial to test whether Artemisia annua extract can prevent ovarian cancer recurrence.
